CRISPR Medicine Insider, 21 February 2020 - CRISPR Medicine

What matters in CRISPR medicine!

It's been a great start to the decade for CRISPR genome editing and gene therapy, and we got You covered on CRISPR Medicine News.

Here is what we have been writing.

The first CRISPR gene therapy is safe
In November, researchers announced the results of the first US CRISPR gene therapy on three patients. Now the data are out in a peer-reviewed paper. Here is our story with comments from leading researcher Carl June and experts in the field.

In vivo genome and base editing with no detectable off-target mutations
Marcello Maresca, the very friendly genome editing wiz at AstraZeneca, gave us an interview. He talks about doing in vivo CRISPR genome editing without detectable off-target mutations and using CRISPR to make disease models and gene therapy.

Anti-CRISPR proteins: A smart way to make gene therapy safer
The CRISPR kill-switch can make gene therapy safer. The latest research describes a new principle of kinetic insulation using anti-CRISPR proteins to increase the specificity of CRISPR-Cas genome editing by tenfold or more.

Gene therapy against lethal chemical warfare nerve agents
Last but not least, 'roundup' soldiers may be a thing in the future. US Army researchers develop an innovative gene therapy in mice that could give soldiers long-lasting protection against lethal nerve agents such as sarin.

More good reads

Top picks



Uh ah wow

  • Curious about the new online resource - The Global Gene Regulation Tracker - from the Genetic Literacy Project? Listen to The Talking Biotech podcast.

  • UK Parliamentary Office publishes brief on human germline genome editing.

  • Biohacking CRISPR, reports on gene editing 'kitchen experiments', EU regulators are struggling to safeguard the new developments.

And that's it

Thank You for now - more great reads are on the way.

And if you have questions or suggestions, you can directly reach us at We love hearing from readers!

(c; Rasmus


You can follow the blog on Twitter and LinkedIn. If someone forwarded this email to you, you can sign up yourself here.